Yong Wang

Yong Wang

Auto-generated profile, based on publicly available information

Yong Wang

Department of Neurology Zhongshan Hospital, Fudan University Shanghai China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2020 in Neural Plasticity
Verified
Journal Article
Open access
PDF file
XLXutong Li
Xutong Li
YZYe Zhang
Ye Zhang
YWYong Wang
Yong Wang
DZDan Zhao
Dan Zhao
CSChengcheng Sun
Chengcheng Sun
JZJing Zhao
Jing Zhao
Background. Ischemic stroke is a severe acute cerebrovascular disease which can be improved with neuroprotective therapies at an early stage. However, due to the lack of effective neuroprotective drugs, most stroke patients have varying degrees of long-term disability. In the present study, we investigated the role of exosomes derived from CXCR4-overexpressing BMSCs in restoring vascular function and neural repair after ischemic cerebral infarction. Methods. BMSCs were transfected with lentivirus encoded by CXCR4 (BMSCCXCR4). Exosomes derived from BMSCCXCR4 (ExoCXCR4) were isolated and characterized by transmission electron microscopy and dynamic light scattering. Western blot and qPCR were used to analyze the expression of CXCR4 in BMSCs and exosomes. The acute middle cerebral artery occlusion (MCAO) model was prepared, ExoCXCR4 were injected into the rats, and behavioral changes were analyzed. The role of ExoCXCR4 in promoting the proliferation and tube formation for angiogenesis and protecting brain endothelial cells was determined in vitro. Results. Compared with the control groups, the ExoCXCR4 group showed a significantly lower mNSS score at 7 d, 14 d, and 21 d after ischemia/reperfusion ( ). The bEnd.3 cells in the ExoCXCR4 group have stronger proliferation ability than other groups ( ), while the CXCR4 inhibitor can reduce this effect. Exosomes control (ExoCon) can significantly promote the migration of bEnd.3 cells ( ), while there was no significant difference between the ExoCXCR4 and ExoCon groups ( ). ExoCXCR4 can further promote the proliferation and tube formation for the angiogenesis of the endothelium compared with ExoCon group ( ). In addition, cobalt chloride (COCl2) can increase the expression of β-catenin and Wnt-3, while ExoCon can reduce the expression of these proteins ( ). ExoCXCR4 can further attenuate the activation of Wnt-3a/β-catenin pathway ( ). Conclusions. In ischemia/reperfusion injury, ExoCXCR4 promoted the proliferation and tube formation of microvascular endothelial cells and play an antiapoptotic role via the Wnt-3a/β-catenin pathway.

1 April 2019 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YWYong Wang
Yong Wang
XLXiao-Ting Lou
Xiao-Ting Lou
YSYi-Hua Shi
Yi-Hua Shi
QTQiang Tong
Qiang Tong
GZGq_Zheng Zheng
Gq_Zheng Zheng

19 August 2025 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
ZZZengyu Zhang
Zengyu Zhang
RJRong Ji
Rong Ji
ZLZhuohang Liu
Zhuohang Liu
ZJZhiwen Jiang
Zhiwen Jiang
MCMin Chu
Min Chu
JZJing Zhao
Jing Zhao
Ischemic stroke induces profound neuroinflammation, where microglial activation exacerbates secondary brain injury. Human umbilical mesenchymal stem cell-derived exosomes (hUMSC-Exos) exhibit therapeutic potential, but their mechanisms in modulating microglial responses remain incompletely understood. Following intranasal administration, hUMSC-Exos selectively accumulated in ischemic brain regions and were internalized by microglia. In transient middle cerebral artery occlusion (tMCAO) mice, hUMSC-Exos improved neurological outcomes, reduced neuronal apoptosis, and promoted a sustained shift in microglial polarization toward an anti-inflammatory phenotype—evidenced by suppressed pro-inflammatory and elevated anti-inflammatory markers in peri-infarct areas. These effects were replicated in LPS/IFN-γ-stimulated primary microglia and BV2 cells. Microglia-specific RNA sequencing revealed that hUMSC-Exos reversed tMCAO-induced pro-inflammatory and migratory transcriptional programs, concurrently suppressing p38 MAPK while activating immunoregulatory pathways. TREM1 emerged as a critical node, with hUMSC-Exos downregulating its expression in microglia; pharmacological TREM1 inhibition (LP17) synergistically augmented the suppression of microglial activation, migration, and proliferation. Mechanistically, hUMSC-Exos attenuated NF-κB/p38 MAPK signaling, with TREM1 functioning upstream of p38 (validated by overexpression/reversal). Proteomic analysis identified HMGB1 as a key exosomal cargo—its blockade (glycyrrhizin) partially reversed hUMSC-Exos-mediated effects, restoring TREM1 expression and pro-inflammatory cytokine release, thus positioning HMGB1 upstream of TREM1. Our findings delineate a novel HMGB1-TREM1-p38 MAPK axis through which hUMSC-Exos mitigate post-stroke neuroinflammation. By delivering HMGB1, hUMSC-Exos inhibit TREM1-dependent NF-κB/p38 activation, reprogram microglial function, and confer neuroprotection. Validated across in vivo, primary, and BV2 microglial models, and supported by multi-omics analyses, this study establishes hUMSC-Exos as a promising cell-free therapy targeting microglial reprogramming for ischemic stroke recovery.

15 October 2020 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
JZJing Zhao
Jing Zhao
YWYong Wang
Yong Wang
MFMarc Fisher
Marc Fisher
RLRenyu Liu
Renyu Liu
Background: In this brief report, we investigated the impact of COVID‐19 on outpatient stroke clinics and inpatient services and their recovery process.Methods: We sent a survey to physicians worldwide through the network of the World Stroke Organization to investigate the impact of COVID‐19 on stroke clinics. To farther along in recovering from the outbreak, we reviewed stroke and other neurology outpatient clinic visits (approximately 50% were stroke related) and the number of inpatient services from December 2019 to July 2020 in a large neurology department in Shanghai, China, where there was no official city lockdown.Results: We received 112 valid survey responses from 46 countries, representing all continents except for Antarctica. Only seven of the survey responders (7/112, 6.3%) reported that they have kept their outpatient clinics open as usual, but they did exercise increased precautions for COVID‐19 by following recent guidelines regarding use of personal protective equipment and isolation techniques. The remainder of the respondents have either reduced outpatient clinic services or suspended outpatient clinics completely. Telephone consultation or telemedicine with video capability was used for new patients or follow‐ups, with limited in‐person evaluations when necessary. Outpatient clinic visits and inpatient services from a large tertiary hospital in China decreased dramatically during the peak period of the outbreak, but then rebounded back quickly following the partial or full recovery from the outbreak. Compared with the recovery process of inpatient services, outpatient clinic visits decreased faster and recovered much slower. This is consistent with our global survey data which indicates that some outpatient clinics have rescheduled their outpatient visits for 3 to 6 months.Conclusions: The COVID‐19 pandemic caused a significant drop of in‐person outpatient visits and inpatient services. Clinic visits recovered slower than inpatient services in stroke and other neurological diseases after the pandemic.

15 April 2025 in Medcomm
Verified
Journal Article
Open access
ZZZengyu Zhang
Zengyu Zhang
DRDewen Ru
Dewen Ru
ZLZhuohang Liu
Zhuohang Liu
ZGZimin Guo
Zimin Guo
LZLei Zhu
Lei Zhu
JZJing Zhao
Jing Zhao
Chronic cerebral hypoperfusion (CCH) is a significant factor that accelerates cognitive deterioration, yet the mechanisms of hippocampal microglial activation in this context remain unclear. Using an integrative multiomics approach, we investigated the transcriptional and epigenomic landscape of microglial activation in a mouse model of CCH induced by bilateral common carotid artery stenosis. Behavioral assessments revealed cognitive impairments, while neuropathological analysis confirmed hippocampal damage. Proteomic and transcriptomic profiling uncovered significant upregulation of stress and inflammatory pathways, particularly the interferon (IFN) signaling cascade. Epigenomic analysis identified regions of open chromatin, suggesting active transcriptional regulation driven by the transcription factor (TF) PU.1. ChIP‐nexus analysis further confirmed that PU.1 directly modulates the expression of IFN‐stimulated genes (ISGs), which are pivotal in regulating microglial activation. Our findings demonstrate that PU.1 serves as a key regulator of the IFN‐driven microglial response during CCH, mediated by enhanced chromatin accessibility and transcriptional activation of ISGs. This study highlights the critical role of PU.1 in microglial‐mediated neuroinflammation and offers potential therapeutic targets for mitigating hippocampal damage associated with chronic cerebral ischemia.

6 May 2025 in Stroke
Verified
Journal Article
Open access
HNHuicong Niu
Huicong Niu
YWYong Wang
Yong Wang
NYNing Yang
Ning Yang
MCMin Chu
Min Chu
XMXueyu Mao
Xueyu Mao
JZJing Zhao
Jing Zhao
BACKGROUND: The mechanism of the lipid paradox remains uncertain, and malnutrition may be 1 explanation. In this prospective cohort study, we explored the associations between baseline remnant cholesterol (RC) concentrations and clinical outcomes in patients with ischemic stroke, stratified by nutritional status. METHODS: Patients with ischemic stroke in a single-center prospective cohort (Shanghai, China) from January 2018 to December 2022 were studied. Individuals were classified into 3 groups based on their Controlling Nutritional Status score. Poor outcome and all-cause mortality during up to 3 months of follow-up were compared among patients with varied nutritional status and RC levels utilizing multivariate logistic regression analyses, RC splines, and subgroup analyses. RESULTS: A total of 6892 patients with ischemic stroke were enrolled in the cohort, of which 5257 patients were included in the present study (without malnutrition: 2418 [46.0%]; mild malnutrition: 2516 [47.9%]; moderate-severe malnutrition: 323 [6.1%]). The median age was 69±12 years, and 3398 (64.6%) were male. Patients with moderate-severe malnutrition had the highest risks of poor outcome (198 [61.3%]; P <0.001) and all-cause mortality (106 [32.8%]; P <0.001) during the 3-month follow-up. A higher baseline RC level was an independent protective factor for adverse outcomes in patients with any degree of malnutrition ( P <0.05), which was not observed in patients without malnutrition. In addition, compared with the moderate-severely malnourished with RC <0.471 mmol/L, the adjusted odds ratios for poor outcome and all-cause mortality were 0.805 (95% CI, 0.450–1.438) and 0.898 (0.502–1.607) for participants with 0.471 to 0.632 mmol/L, 0.259 (0.095–0.704) and 0.222 (0.061–0.810) for 0.633 to 0.868 mmol/L, and 0.160 (0.037–0.689) and 0.202 (0.042–0.967) for ≥0.869 mmol/L, respectively. CONCLUSIONS: The lipid paradox was only observed in the malnourished patients with ischemic stroke. Strict lipid reduction therapy is still recommended for patients without malnutrition. However, when treating patients at any risk of malnutrition, the improvement of nutritional status may be more crucial.